[1] http://www.cancer-treatment-tips.com/cancer-statistics.html.
[2] Virgolini, K. Britton, J. Buscombe, R. Moncayo, G. Paganelli and P. Riva, “In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.” Semin Nucl Med, Vol. 32, pp. 148-155, 2002.
[3] J. Kwekkeboom, J. J. Teunissen, W.H. Bakker, P. P .Kooij, W. W. de Herder, R. A. Feelders, C. H. van Eijck, J. P. Esser , B. L. Kam and E. P. Krenning, “Radiolabeled somatostatin analog (177Lu-DOTA0,Tyr3)octreotate in patients with endocrine gastroenteropancreatic tumors.” J Clin Oncol, Vol. 23, pp. 2745-2762, 2005.
[4] R. Valkema, S. Pauwels, L. K. Kvols, R. Barone, F. Jamar, W. H. Bakker, D. J. Kwekkeboom , H. Bouterfa and E. P. Krenning, “Survival and response after peptide receptor radionuclide therapy with (90Y-DOTA0)octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.” Semin Nucl Med, Vol. 36, pp. 147-156, 2006.
[5] J. Kwekkeboom, W. W. de Herder, B. L. Kam, C. H. van Eijck, M. van Essen, P.P. Kooij, R. A. Feelders , M. O. van Aken and E. P. Krenning , “Treatment with the radiolabeled somatostatin analog (177Lu-DOTA0, Tyr3)octreotate: toxicity, efficacy and survival.” J Clin Oncol, Vol 26, pp. 2124-2130, 2008.
[6] J. C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J. E. Mares, E. K. Abdalla, J. B. Fleming, J. N. Vauthey, A. Rashid and D. B. Evans et al. “One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.” J Clin Oncol, vol. 26, pp. 3063-3072, 2008.
[7] L. Bodei, M. Cremonesi, C. Grana, P. Rocca, M. Bartolomei, M. Chinol, and G. Paganelli, “Receptor radionuclide therapy with 90Y-(DOTA)0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.” Eur J Nucl Med Mol Imaging, vol. 31, pp. 1038-1046, 2004.
[8] J. Kwekkeboom, J. Mueller-Brand, G. Paganelli, L. B. Anthony, S. Pauwels, L. K. Kvols, T. M. O'dorisio, R. Valkema, L. Bodei , M. Chinol, H. R. Maecke and E. P. Krenning . “Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.” J Nucl Med, vol. 46, pp. 62-66, 2005.
[9] G. Harris, “Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.” Gut, vol. 35, pp. 1-4, 1994.
[10] Wehrmann, S. Senftleben, C. Zachert, D. Müller and R. P. Baum, “Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.” Cancer Biother Radiopharm, vol. 22, pp. 406-416, 2007.
[11] J. Kwekkeboom, W. H. Bakker, J. J. M. Teunissen, et al. “Treatment with Lu-177- DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results (abstract). ”Eur J Nucl Med Mol Imaging, vol. 30, pp. 231, 2003.
[12] Otte, R. Herrmann, A. Heppeler, M. Behe, E. Jermann, P. Powell, H. R. Maecke and J. Muller, “Yttrium-90 DOTATOC: first clinical results.” Eur J Nucl Med, vol.26, pp. 1439 –1447, 1999.
[13] H. Yousefnia, M. Mousavi-Daramoroudi, S. Zolghadri and F. Abbasi-Davani, “Preparation and biodistribution assessment of low specific activity 177Lu-DOTATOC for optimization studies.” Iran J Nucl Med, vol. 24, pp. 85-91, 2016.
[14] K. Bogen, “Simulation software for the Macintosh.” Science, vol. 246, pp. 138-142, 1989.
[15] M. Foster and R. C. Boston, The use of computers in compartmental analysis: the SAAM and CONSAM programs. Boca Raton: USA, 1983, pp. 73-142.
[16] J. A. Jacquez, “Compartmental analysis in biology and medicine.” Ann Arbor: University of Michigan Press, pp. 277–310, 1985.
[17] H. Anderson, “Compartmental modeling and tracer kinetics.” New York: Springer-Verlag, pp. 302, 1983.
[18] R. E. Carson, “Tracer kinetic modeling in PET.” in Positron emission tomography: basic sciences, 2nd ed. D. L. Bailey, D. W. Townsend, P. E. Valk, M. N. Maisey, Eds. London, UK: Springer, 2005, pp. 127–159.
[19] M. L. Ralston, R. I. Jennrich, P. F. Sampson, et al. Fitting pharmacokinetic models with BMDPAR, BMDP technical report no. 58. Los Angeles: UCLA Health Sciences Computing Facilities, 1979.
[20] J. A. Siegel, S. R. Thomas, J. B. Stubbs, M. G. Stabin, M. T. Hays, K. F. Koral, J. S. Robertson, R. W. Howell, B. W. Wessels, D. R. Fisher, D. A. Weber and A. B. Brill, “MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.” J Nucl Med, vol. 40, pp. 37-61, 1999.
[21] Jalilian, S. Shanehsazzadeh, M. Akhlaghi, J. Garoosi, S. Rajabifar and M. Tavakoli, “Preparation and evaluation of (67Ga)-DTPA-β-1–24-corticotrophin in normal rats.” Radiochim Acta, vol. 96, pp. 435-439, 2008.
[22] Anderson, Compartmental modeling and tracer kinetics. Berlin: Springer-Verlag, 1983.
[23] J. A. Jacquez, Compartmental analysis in biology and medicine. Amsterdam, Holland: Elsevier/North, 1972.